<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-03-19">19 March 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Alois</forename><surname>Gratwohl</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">The European Society for Blood and Marrow Transplantation (EBMT) Activity Survey Office</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<postCode>CH-4031</postCode>
									<settlement>Basel, Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simona</forename><surname>Iacobelli</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Centro Interdipartimentale di Biostatistica e Bioinformatica</orgName>
								<orgName type="institution">Università di Roma Tor Vergata</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Natalia</forename><surname>Bootsman</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">EBMT Data Office Leiden</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Van Biezen</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">EBMT Data Office Leiden</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Helen</forename><surname>Baldomero</surname></persName>
							<email>helen.baldomero@usb.ch</email>
							<affiliation key="aff0">
								<orgName type="laboratory">The European Society for Blood and Marrow Transplantation (EBMT) Activity Survey Office</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<postCode>CH-4031</postCode>
									<settlement>Basel, Basel</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><surname>Arcese</surname></persName>
							<affiliation key="aff3">
								<orgName type="laboratory">Stem Cell Transplant Unit</orgName>
								<orgName type="institution" key="instit1">Rome Transplant Network</orgName>
								<orgName type="institution" key="instit2">¨Tor Vergata¨University of Rome</orgName>
								<orgName type="institution" key="instit3">Policlinico Universitario Tor Vergata</orgName>
								<address>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Arnold</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Hematology-Oncology</orgName>
								<orgName type="institution">Charité Universitätsmedizin</orgName>
								<address>
									<addrLine>Campus Virchow Klinikum</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominique</forename><surname>Bron</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Experimental Hematology</orgName>
								<orgName type="department" key="dep2">Institut Jules Bordet</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Catherine</forename><surname>Cordonnier</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Hôpital Mondor</orgName>
								<address>
									<settlement>Hematology, Créteil</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Ernst</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">King Faisal Specialist Hospital &amp; Research Centre, Oncology</orgName>
								<orgName type="institution">Section of Adult Haematolgy/BMT</orgName>
								<address>
									<settlement>Riyadh</settlement>
									<country key="SA">Saudi Arabia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Augustin</forename><surname>Ferrant</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Cliniques Universitaires St. Luc</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Francesco</forename><surname>Frassoni</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Haematology II</orgName>
								<orgName type="institution">Ospedale San Martino</orgName>
								<address>
									<settlement>Genova</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gösta</forename><surname>Gahrton</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlos</forename><surname>Richard</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">Hospital U. Marqués de Valdecilla</orgName>
								<orgName type="institution" key="instit2">Servicio de Hematología-Hemoterapia, c/ Marqués de Valdecilla</orgName>
								<address>
									<settlement>Santander</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hans</forename><forename type="middle">Jochem</forename><surname>Kolb</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Klinikum Grosshadern, Med. Klinik III</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hartmut</forename><surname>Link</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Medizinische Hochschule Hannover</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dietger</forename><surname>Niederwieser</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Universitätsklinikum</orgName>
								<address>
									<settlement>Hämatologie, Innsbruck</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tapani</forename><surname>Ruutu</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">University of Helsinki Hospital</orgName>
								<address>
									<settlement>Helsinki</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anton</forename><surname>Schattenberg</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Radboud University Medical Center</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Norbert</forename><surname>Schmitz</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Asklepios Klinik St. Georg</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Antonio</forename><surname>Torres-Gomez</surname></persName>
							<affiliation key="aff20">
								<orgName type="institution">Hematology, Hospital Reina Sofia</orgName>
								<address>
									<settlement>Córdoba</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ferry</forename><surname>Zwaan</surname></persName>
							<affiliation key="aff21">
								<orgName type="institution">Leiden University Medical Center</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jane</forename><surname>Apperley</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution" key="instit1">Imperial College</orgName>
								<orgName type="institution" key="instit2">Hammersmith Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eduardo</forename><surname>Olavarria</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Haematology</orgName>
								<orgName type="institution">Complejo Hospitalario de Navarra</orgName>
								<address>
									<settlement>Pamplona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ospedale</forename><surname>Gaslini</surname></persName>
						</author>
						<author>
							<persName><roleName>Italy</roleName><surname>Genova</surname></persName>
						</author>
						<author>
							<affiliation key="aff14">
								<address>
									<settlement>Westpfalzklinikum, Kaiserslautern</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Hematology-Oncology</orgName>
								<orgName type="institution">University Hospital</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="institution" key="instit1">Hematology</orgName>
								<orgName type="institution" key="instit2">University Hospital Hamburg</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-03-19">19 March 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">2CD1D07FC5E2C892D831AA48E088565A</idno>
					<idno type="DOI">10.1007/s00277-016-2638-6</idno>
					<note type="submission">Received: 28 January 2016 / Accepted: 7 March 2016 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:50+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>HSCT</term>
					<term>CML</term>
					<term>Splenic irradiation</term>
					<term>Randomized trial</term>
					<term>Long-term follow-up</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML).</s><s>Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated.</s></p><p><s>Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4</s><s>% vs 52.9 %, 43.2-62.6</s><s>%; p = 0.355, log rank test).</s><s>Additional splenic irradiation failed to reduce relapse incidence.</s><s>It did not increase non-relapse mortality nor the risk of late secondary malignancies.</s><s>Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they * Helen Baldomero</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>When hematopoietic stem cell transplantation (HSCT) was introduced as a novel approach for patients with chronic myeloid leukemia (CML) half a decade ago, the transplant was primarily performed in advanced disease stage.</s><s>Debulking of the tumor load by removing the big spleen, a then hallmark of disease progression, was considered essential.</s><s>Splenectomy or splenic irradiation was performed routinely prior to the transplant <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Retrospective observational cohort studies failed to confirm a benefit of splenectomy <ref type="bibr" target="#b2">[3]</ref>.</s><s>Consequently, a prospective randomized study was initiated by the European Society for Blood and Marrow Transplantation (EBMT) to investigate the potential role of splenic irradiation.</s><s>Early results and an update with a 3-year follow-up showed no significant differences between the groups <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>Splenectomy and splenic irradiation were abandoned.</s><s>Interest into this question further diminished with the advent of targeted therapy for CML by tyrosine kinase inhibitors (TKI) <ref type="bibr" target="#b5">[6]</ref>.</s><s>Numbers of HSCT for CML rapidly declined; HSCT became considered as salvage therapy for patients refractory to lines of TKIs or for those in advanced phase of the disease or in blast crisis <ref type="bibr" target="#b6">[7]</ref>.</s></p><p><s>The topic of both questions, the place of HSCT in the treatment algorithm for CML and the role of splenic pre-treatment has regained interest in recent years, for several reasons.</s><s>Myeloproliferative neoplasias other than CML have become a target for HSCT; optimal management of patients with splenomegaly before HSCT has become a matter of debate <ref type="bibr" target="#b7">[8]</ref>.</s><s>Recently reported excellent results with early transplants for selected patients with a low risk transplant donor have renewed interest in HSCT <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>Increasing awareness of cost effectiveness considerations might favor earlier HSCT in patients non-responding to first-line TKI but with low transplant risks rather than long-term TKI treatment <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>And, recent discussions about reproducibility of clinical study results mandate a second look beyond shortterm outcome <ref type="bibr" target="#b12">[13]</ref>.</s><s>In this context, long-term outcome of a predefined group becomes of interest.</s><s>The Chronic Malignancies Working Party of the EBMT has therefore undertaken the efforts to have a second look at this defined study cohort and to update the results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head><p><s>This analysis was based on the prospective randomized study conducted between 1986 and 1989 <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>A total of 229 patients with CML in first chronic phase and planned to undergo HSCT from an HLA-identical donor were randomized not to receive (N = 115) or to receive (N = 114) splenic irradiation in one of three options, 10 Gy single dose, 5 Gy in two doses, or 3.3 Gy in three doses.</s><s>Randomization was performed centrally in blocks of six patients, stratified by age (≤25 years, &gt;25 years) and whether or not T cell depletion (TCD) was used.</s><s>The Ethics Committee of the then Kantonsspital Basel, now University Hospital Basel, approved the protocol; all patients gave informed consent.</s></p><p><s>Of these 229 patients, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the current CMWP data file.</s><s>Their characteristics are listed in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Not all remained in chronic phase until the time of transplant; in some, the diagnosis of CML was modified to MDS or MPN over time, according to the then available diagnostic tools.</s><s>The analysis followed the intention to treat principle.</s><s>All patients randomized to splenic irradiation indeed were treated accordingly and received splenic irradiation; none of the patients randomized to no splenic irradiation did receive splenic irradiation.</s><s>Their survival status was updated as of January 1, 2015, with a median follow-up time of the living patients of 239 months (7-335 months, range).</s><s>Main endpoint of the analysis was overall survival by randomization group using Cox regression as model.</s><s>Comparisons were adjusted for the stratification (T cell depletion; TCD+ and TCD−), the EBMT risk score <ref type="bibr" target="#b13">[14]</ref>, and the number of basophils in the circulating blood prior to HSCT (baso &lt;3 vs ≥3 %).</s><s>Secondary endpoints were relapse incidence, non-relapse mortality, which includes any death without relapse and relapse free survival.</s><s>An additional secondary endpoint was the probability of developing a secondary malignancy.</s><s>Note that all patients were diagnosed as CML and classified as CML at time of randomization.</s><s>Some of them were diagnosed as Ph-negative CML, according to the state of the art at that time; some of them were re-labeled as myeloproliferative neoplasia or myelodysplastic syndrome later in the course.</s><s>All were kept in the analysis in order to follow the intention to treat principle.</s><s>EBMT risk score: for definitions, see <ref type="bibr" target="#b13">(Gratwohl 2012)</ref> CML chronic myeloid leukemia, MDS/MPN myelodysplastic syndrome/myeloproliferative neoplasia, TCD T cell depletion, baso = basophil count &lt; or ≥3 % at time of randomization, TBI total body irradiation, NRM Non-relapse mortality, REL relapse incidence, Note that some numbers do not add up due to missing values a Stage of disease at time of transplant: note that all patients were in first chronic phase at time of randomization; some progressed during waiting.</s><s>They were included in the analysis according to the intention to treat principle b There were no significant differences between the groups, but note the imbalance for TCD despite TCD being a stratification factor</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Both groups were well balanced concerning their main key pre-transplant risk factors and transplant techniques, with one minor exception (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Despite stratification, we observed a trend towards more patients with TCD+ in the splenic irradiation group (31 vs 20 %; p = 0.062).</s></p><p><s>At the time of the analysis, 113 patients were alive (50.2 %), 112 (49.8 %) had died, 84 (75 %) of them from non-relapse mortality, and 28 (25 %) from relapse.</s></p><p><s>Probabilities of overall survival at 15 and 25 years for the whole group were 49.6 and 47.5 %, respectively.</s><s>Of note, seven of nine patients with EBMT risk score 0 (77 %) and 36 of 63 patients with EBMT risk scores 0 and I were still alive (57 %) in contrast to 6 of 15 (40 %) with risk scores IV and V and 1 of 3 (33 %) with risk score V.</s></p><p><s>The comparison of patients without or with splenic irradiation confirmed the early findings, presented 20 years ago, with no significant differences between groups in overall survival (at 15 years: 45.3 %, 35.7-54.9</s><s>% vs 54.2 %, 44.6-63.8</s><s>%; at 25 years: 42.7 %, 32.0-52.4</s><s>% vs 52.9 %, 43.2-62.6</s><s>%; p = 0.355, log rank test), non-relapse mortality (at 15 years: 38.3 %, 29.1-47.5 % vs 35.8 %, 26.7-44.8</s><s>%; at 25 years: 41.0 %, 31.5-50.5 % vs 37.1 %, 27.9-46.4</s><s>%; p = 0.803, Gray test), relapse incidence (at 15 years: 27.5 %, 19.0-35.9</s><s>% vs 27.5 %, 18.9-36.0</s><s>%; at 25 years: 27.5 %, 19.0-35.9</s><s>% vs 30.0 %, 20.4-39.5 %; p = 0.977, Gray test), and relapse-free survival (at 15 years: 34.2 %,25.1-43.4</s><s>% vs 36.8 %, 27.5-46.1 %;at 25 years: 31.5 %, 22.3-40.7 % vs 32.9 %, 23.0-42.8</s><s>%, p = 0.745, logrank test) (Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>Both treatment arms were compared for the stratification factor (TCD+/−) and the basophil count (&lt;3 %/≥3 %) in the four TCD/basophil count groups.</s><s>There were no significant differences in any of the four endpoints in any of the four groups in univariate as well as multivariate analysis.</s><s>A suggested trend from the last analysis <ref type="bibr" target="#b4">[5]</ref> for better survival with splenic irradiation in the TCD+/≥3 % basophils could not be substantiated at long-term follow-up.</s><s>There were no significant differences in the causes of death (Table <ref type="table" target="#tab_0">1</ref>; p = 0.573), and there was no difference in the probability of developing a secondary malignancy at 25 years (8.7 %, 2.5-14.9</s><s>% vs 10.7 %, 2.3-19.0</s><s>%; p = 0.993, Gray test) (Fig. <ref type="figure" target="#fig_0">1d</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The results confirm the previously published early findings after a follow-up time of now plus 25 years: splenic irradiation did not confer an advantage for patients transplanted with CML nor cause harm.</s><s>These results are comforting, despite the absence of a benefit.</s><s>The early results could be substantiated; a suggested trend in one of the subgroups of TCD+ patients was not verified.</s><s>Additional splenic irradiation prior to the transplant failed to reduce relapse incidence.</s><s>It did as well not increase the risk of non-relapse mortality nor the risk of late secondary malignancies.</s></p><p><s>There is no need to reconsider the initial question.</s><s>Splenic irradiation is no longer of interest for patients with CML.</s><s>The results of this long-term follow-up study might, in contrast, be of relevance in today's discussion concerning the role of splenectomy or splenic irradiation for patients with other myeloproliferative disorders <ref type="bibr" target="#b7">[8]</ref>.</s><s>It is likely that the observations from patients with CML hold true as well for patients with splenomegaly but other myeloproliferative disorders.</s></p><p><s>The study adds to and supports the ongoing discussion on reproducibility of clinical studies.</s><s>It documents the potential of investigator initiated studies in follow-up continuation <ref type="bibr" target="#b12">[13,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>Ninety-eight percent of the initial patient cohort could be identified and update be obtained, this with very limited resources and no direct industrial support.</s><s>The results add as well to the discussion on the role and potential of outcome registries.</s><s>They can indeed contribute most valuable information <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>Most satisfying are the long-term results from this predefined consecutive cohort of patients.</s><s>Half of them were alive, more than 25 years after HSCT for CML, more than 60 % when transplanted with a low EBMT risk sore.</s><s>This needs to be considered when treatment options are discussed for patients who failed initial TKI therapy in still early disease but have an available low risk HLA-identical donor <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b9">10]</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Outcome of 225 patients with HLA-identical sibling donor HSCT for CML and randomized to splenic irradiation or not.</s><s>The graph depicts probabilities according the intention to treat analysis by months post HSCT and the numbers of patients at risk at the given time points in the</s></p></div></figDesc><graphic coords="5,51.08,191.74,493.37,479.17" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Patients' characteristics by randomization group</s></p></div></figDesc><table><row><cell>No splenic irradiation (N (%))</cell><cell>Splenic irradiation (N (%))</cell><cell>Total (N (%))</cell><cell>P value</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">c  The four strata did present different characteristics for calendar year (p = 0.007, but with no monotonic trend; p = 0.955), diagnosis (p = 0.003), patient gender (p = 0.020), donor age (p = 0.086), and donor age (p = 0.039). The analyses, taking into account the strata, were carried out by multivariable models adjusted for these factors</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Ann Hematol (2016) 95:967-972</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgments The authors would like to thank all participating patients and transplant teams.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Compliance with ethical standards</head><p><s>McKinnon); Munich: Ludwig Maximilian University Hospital (H.J. Kolb, W.Hiddemann, J. Tischer); Nijmegen: Sint Radboud Ziekenhuis (T.</s><s>deWitte, T. Schattenberg, N. Schaap); Paris: Centre Hospitalier St. Antoine (N.C.</s><s>Gorin, L.Fouillard, M. Mohty); Pessac: Centre Hospitalier (J.</s><s>Reiffers, N. Millpied); Riyadh: King Faisal Hospital (P.</s><s>Ernst, M. Aljurf); Rome: UniversitadegliStudi di Roma La Sapienza (W.</s><s>Arcese, P. de Fabritiis, R. Foa); Santander: Hospital Nacional BMarques de Valdecilla^(A.</s><s>Iriondo, C. Richard Espiga); Vienna: Allgemeines Krankenhaus der Stadt Wien (W.</s><s>Hinterberger, P. Kahls)</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of interest</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Baughan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mccarthy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">8299</biblScope>
			<biblScope unit="page" from="623" to="625" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Successful allogeneic bone-marrow transplantation for patients in the accelerated phase of chronic granulocytic leukaemia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Mcglave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Arthur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Ramsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Hurd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kersey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">8299</biblScope>
			<biblScope unit="page" from="625" to="627" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Effect of splenectomy before bone-marrow transplantation on survival in chronic granulocytic leukaemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gluckman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zwaan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">8467</biblScope>
			<biblScope unit="page" from="1290" to="1291" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: results of a prospective randomized study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Biezen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="147" to="152" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hermans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Biezen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="494" to="500" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">348</biblScope>
			<biblScope unit="page" from="994" to="1004" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">European LeukemiaNet recommendations for the management of chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Deininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="872" to="884" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Akagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kawabata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ichinohe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Takaori-Kondo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tohoku J Exp Med</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="295" to="299" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pfirrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zander</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2015.281</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ito</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="3230" to="3235" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Hematopoietic stem cell transplantation: a global perspective</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Baldomero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aljurf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">303</biblScope>
			<biblScope unit="page" from="1617" to="1624" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Pasquini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hematology</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="S79" to="S82" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Reanalyses of randomized clinical trial data</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ebrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">N</forename><surname>Sohani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Montoya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="page" from="1024" to="1032" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">The EBMT risk score</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="749" to="756" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Optimizing investigatorled oncology research in Europe</title>
		<author>
			<persName><forename type="first">T</forename><surname>Barbui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Björkholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gratwohl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="800" to="804" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Methodological challenges in evaluating the value of registers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Patrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lyratzopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Technol Assess Health Care</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="28" to="33" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
